SOHO 2026 | Outcomes from a MAIC comparing epcoritamab-R-squared with tafasitamab-R-squared in R/R FL

So this is important because we had the publication of the EPCORE FL-1 and the inMIND trial data at the same time. One was looking at epcoritamab in combination with R-squared versus R-squared and the other was looking at tafasitamab-R-squared versus R-squared. And there’s no randomized head-to-head comparison to decide which of these treatments is better. So we did an anchored matching adjusted indirect treatment comparison or a MAIC. And the anchored part is because the comparator is the same in both arms. So both trials compared with rituximab and lenalidomide. And I think what’s really helpful here is that there was, when we look at the effective sample size, in other words, the proportion of patients that were retained from the EPCORE FL-1 study, we retained over 80% of that patient population. So that suggests that we were retaining the majority of patients for that comparison, which means it’s a very reliable comparator. So the fact that it’s anchored and the fact that we’ve got a very high effective sample size means it’s a very robust comparison. And what the conclusion of that poster was is that EPCORE R-squared is superior to tafasitamab R-squared pretty much across all of the outcome measures. So we saw higher overall response rates, 93 versus 81%, but predominantly we saw more CR rates so more complete metabolic responses and we saw a longer duration of complete metabolic response for the EPCORE patients compared to the duration of complete response for the R-squared patients so we are definitely driving a deeper immunological destruction of cells and that then translated to a longer time to next treatment. So more patients benefited over a longer time horizon from the EPCORE R-squared versus the tafasitamab R-squared. What we didn’t do in the indirect treatment comparison was look at safety. So it is important to acknowledge that and to say that when you are looking at these therapies, obviously there’s the choice around efficacy, but you also have to balance that against safety. And undoubtedly, EPCORE R-squared is associated with more adverse events, serious adverse events, than tafasitamab R-squared. So it’s an option for patients, like we were discussing earlier on, with higher risk disease, whereas tafasitamab R-squared is probably a good option for those who can’t tolerate the triplet or potentially have lower risk disease.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.